生物技术公司Intellia Therapeutics Inc公布了其候选疗法Lonvoguran Ziclumeran（研发代号Lonvo-Z）在治疗遗传性血管性水肿患者中的最新3期临床试验数据，结果显示出持续的积极疗效与安全性。
此次公布的数据进一步巩固了该疗法在关键后期研究中的表现，为后续的监管申请提供了有力支持。遗传性血管性水肿是一种罕见的遗传性疾病，患者会反复出现皮下或黏膜下组织的严重肿胀，目前仍存在未满足的临床需求。
公司表示，这些额外的积极结果增强了他们对Lonvo-Z潜力的信心，并计划持续推进相关开发工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.